BioPharmSignal logoBioPharmSignal

Biotech News

Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director

Arvinas, Inc. (ARVN)Arvinas, Inc.Company update

– Appointment of an experienced Arvinas executive with a proven ability to drive strategy and innovation positions the company for continued momentum and long-term growth – NEW HAVEN, Conn., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company

Related news

ARVNArvinas, Inc.2026-03-11 11:00 EST

Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders

ARVNArvinas, Inc.2026-03-18 11:00 EST

Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days

NRIXNurix Therapeutics2026-08-20 11:00 EST

Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer

BCRXBioCryst Pharmaceuticals2026-04-06 11:00 EST

BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer

KYMRKymera2026-07-27 20:01 EST

Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer

BCRXBioCryst Pharmaceuticals2026-07-15 11:00 EST

BioCryst Appoints David W. Jenkins as Chief Scientific Officer

GSKGSK plc2026-07-09 10:00 EST

Roy Jakobs to join GSK Board as Non-Executive Director

PHARPharming Group2026-07-30 05:00 EST

Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic use

NRIXNurix Therapeutics2026-07-21 20:01 EST

Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

KYMRKymera2026-05-15 11:00 EST

Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses

View all latest news

Arvinas, Inc.

Arvinas is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

ARVNArvinas, Inc.2026-06-04 12:00 EST

Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease

ARVNArvinas, Inc.2026-05-29 20:01 EST

Arvinas to Present at Jefferies Global Healthcare Conference

ARVNArvinas, Inc.2026-05-18 14:30 EST

Arvinas Employees Give Back During Company-wide Impact Day

ARVNArvinas, Inc.2026-05-12 11:05 EST

Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update

ARVNArvinas, Inc.2026-05-12 11:00 EST

Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)

Stock data

Close
10.78 USD
Market cap
695.5M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States